JP7318876B2 - エステル結合で薬物が固定されたリガンドを含有する超音波造影剤を活用した超音波誘導薬物送達体 - Google Patents
エステル結合で薬物が固定されたリガンドを含有する超音波造影剤を活用した超音波誘導薬物送達体 Download PDFInfo
- Publication number
- JP7318876B2 JP7318876B2 JP2022513987A JP2022513987A JP7318876B2 JP 7318876 B2 JP7318876 B2 JP 7318876B2 JP 2022513987 A JP2022513987 A JP 2022513987A JP 2022513987 A JP2022513987 A JP 2022513987A JP 7318876 B2 JP7318876 B2 JP 7318876B2
- Authority
- JP
- Japan
- Prior art keywords
- drug
- drug delivery
- ester bond
- bound
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0047—Sonopheresis, i.e. ultrasonically-enhanced transdermal delivery, electroporation of a pharmacologically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6925—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a microcapsule, nanocapsule, microbubble or nanobubble
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Nanotechnology (AREA)
- Medicinal Preparation (AREA)
Description
Claims (7)
- 前記リン脂質はジパルミトイルホスファチジルコリン(DPPC)、ジオレオイルホスファチジルコリン(DOPC)、ジステアロイルホスファチジルコリン(DSPC)、ジミリストイルホスファチジルコリン(DMPC)、ジデカノイルホスファチジルコリン(DDPC)、ジラウロイルホスファチジルコリン(DLPC)、ジミリストイルホスファチジルエタノールアミン(DMPE)、ジパルミトイルホスファチジルエタノールアミン(DPPE)、ジステアロイルホスファチジルエタノールアミン(DSPE)、ジオレイルホスファチジルエタノールアミン(DOPE)、ジアラキドイルホスファチジルエタノールアミン(DAPE)、ジリノレイルホスファチジルエタノールアミン(DLPE)、ジパルミトイルホスファチジルグリセロール(DPPG)、ジラウロイルホスファチジルグリセロール(DLPG)、ジステアロイルホスファチジルグリセロール(DSPG)、ジオレオイルホスファチジルグリセロール(DOPG)、ホスファチジルコリン(PC)及び卵黄ホスファチジルコリン(EPC)からなる群から選択されるいずれか1つ以上である
請求項1に記載の薬物送達体。 - 前記薬物送達体は直径0.2乃至10μmのマイクロ又はナノバブル(microbubbles or nanobubbles)を形成するものである
請求項1に記載の薬物送達体。 - 前記薬物送達体は超音波(ultrasonic wave)照射によるバブルの崩壊及びエステル結合の加水分解促進で薬物放出が加速化することを特徴とする
請求項1に記載の薬物送達体。 - 前記薬物送達体はリガンド又はリン脂質の表面に、標的の疾患と関連して発現される収容体に特異的に結合する抗体又は抗体断片又はアプタマーである標的化剤(標的化物質)が追加的に導入されたものである
請求項1に記載の薬物送達体。 - 請求項1ないし5のいずれかに記載の薬物送達体を含む
ことを特徴とする薬物送達用組成物。 - 請求項6に記載の薬物送達用組成物をヒトを除く個体に投与するステップ;及び、
前記組成物が投与された部位に超音波を照射して薬物を放出させるステップを含む
ことを特徴とする疾患の予防又は治療方法。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/KR2020/011512 WO2022045398A1 (ko) | 2020-08-27 | 2020-08-27 | 에스터 결합으로 약물이 고정된 리간드를 함유하는 초음파 조영제를 활용한 초음파 유도 약물전달체 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022552075A JP2022552075A (ja) | 2022-12-15 |
JP7318876B2 true JP7318876B2 (ja) | 2023-08-01 |
Family
ID=80355387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022513987A Active JP7318876B2 (ja) | 2020-08-27 | 2020-08-27 | エステル結合で薬物が固定されたリガンドを含有する超音波造影剤を活用した超音波誘導薬物送達体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220313820A1 (ja) |
EP (1) | EP3988124A4 (ja) |
JP (1) | JP7318876B2 (ja) |
CN (1) | CN114728085A (ja) |
WO (1) | WO2022045398A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114748646B (zh) * | 2022-04-28 | 2023-04-07 | 山东大学 | 一种超声、荧光双重显影负载量子点纳米泡及其制备方法和应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019200043A1 (en) | 2018-04-11 | 2019-10-17 | New Mexico Tech University Research Park Coporation | Lipid prodrugs for use in drug delivery |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0148704B1 (ko) * | 1994-01-10 | 1998-08-17 | 김상응 | 생체분해성 약물전달용 고분자 |
US7368129B1 (en) * | 1996-08-14 | 2008-05-06 | Nutrimed Biotech | Amphiphilic materials and liposome formulations thereof |
EP0973552B1 (en) * | 1996-10-28 | 2006-03-01 | Amersham Health AS | Improvements in or relating to diagnostic/therapeutic agents |
WO2005115337A1 (en) * | 2004-05-24 | 2005-12-08 | Polymun Scientific Immunbiologische Forschung Gmbh | Superloaded liposomes for drug delivery |
WO2006096426A2 (en) * | 2005-03-03 | 2006-09-14 | The Board Of Trustees Of The University Of Illinois | Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization |
GB201106803D0 (en) * | 2011-04-21 | 2011-06-01 | Univ Ulster | Sonodynamic therapy |
CN103930137A (zh) * | 2011-10-13 | 2014-07-16 | 大学健康网络 | 卟啉-磷脂结合物微泡及其作为造影剂的用途 |
CN106727314B (zh) * | 2017-01-13 | 2021-01-01 | 中国药科大学 | 一种基于透明质酸的光敏剂/抗肿瘤药物自组装纳米递药系统的制备与表征 |
-
2020
- 2020-08-27 CN CN202080009295.2A patent/CN114728085A/zh active Pending
- 2020-08-27 EP EP20940475.5A patent/EP3988124A4/en active Pending
- 2020-08-27 WO PCT/KR2020/011512 patent/WO2022045398A1/ko unknown
- 2020-08-27 US US17/424,485 patent/US20220313820A1/en active Pending
- 2020-08-27 JP JP2022513987A patent/JP7318876B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019200043A1 (en) | 2018-04-11 | 2019-10-17 | New Mexico Tech University Research Park Coporation | Lipid prodrugs for use in drug delivery |
Also Published As
Publication number | Publication date |
---|---|
EP3988124A4 (en) | 2023-09-13 |
CN114728085A (zh) | 2022-07-08 |
WO2022045398A1 (ko) | 2022-03-03 |
US20220313820A1 (en) | 2022-10-06 |
JP2022552075A (ja) | 2022-12-15 |
EP3988124A1 (en) | 2022-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gadekar et al. | Nanomedicines accessible in the market for clinical interventions | |
Liang et al. | Nanohybrid liposomal cerasomes with good physiological stability and rapid temperature responsiveness for high intensity focused ultrasound triggered local chemotherapy of cancer | |
Bi et al. | Current developments in drug delivery with thermosensitive liposomes | |
JP6894423B2 (ja) | 融合性リポソーム被覆多孔質ケイ素ナノ粒子 | |
Bisso et al. | Nanopharmaceuticals: A focus on their clinical translatability | |
Yang et al. | Focused ultrasound and interleukin-4 receptor-targeted liposomal doxorubicin for enhanced targeted drug delivery and antitumor effect in glioblastoma multiforme | |
CN100563718C (zh) | 用于反差成像的充气微囊组件 | |
JP5082446B2 (ja) | 被覆磁性粒子含有製剤およびその製造方法、並びに診断治療システム | |
EP2913065A1 (en) | Ultrasound contrast medium in which nanoparticles containing drug are combined, and preparation method therefor | |
Kong et al. | Enhanced transdermal lymphatic drug delivery of hyaluronic acid modified transfersomes for tumor metastasis therapy | |
EP2623097B1 (en) | Solid lipid nanoparticles including elastin-like polypeptides and use thereof | |
CN108066317B (zh) | 纳米药物控释体系的制备方法及其产品与应用 | |
CN105530920B (zh) | 通过纳米结构的载体系统引起的细胞特异性靶向作用 | |
KR101487088B1 (ko) | 약물을 함유한 나노입자가 결합된 초음파 조영제 및 이의 제조방법 | |
Khalili et al. | Smart active-targeting of lipid-polymer hybrid nanoparticles for therapeutic applications: Recent advances and challenges | |
JP7318876B2 (ja) | エステル結合で薬物が固定されたリガンドを含有する超音波造影剤を活用した超音波誘導薬物送達体 | |
CN114558133A (zh) | 一种同时递送声敏剂和靶向抗体的超声靶向微泡及其制备方法和应用 | |
Jang et al. | Development of exosome membrane materials-fused microbubbles for enhanced stability and efficient drug delivery of ultrasound contrast agent | |
CN109568610B (zh) | 一种基于Janus药物共轭体的诊疗微泡的制备方法和用途 | |
Bhagat et al. | Nanocarriers to solid tumors: considerations on tumor penetration and exposure of tumor cells to therapeutic agents | |
JP5491067B2 (ja) | リポソーム、リポソームの製造方法、及び医薬組成物 | |
WO2019200354A1 (en) | Therapeutic nanodroplet double emulsions and methods of use thereof | |
KR20220029810A (ko) | 에스터 결합으로 약물이 고정된 생체물질을 함유하는 초음파 조영제를 활용한 초음파 유도 약물전달체 | |
Abuwatfa et al. | In vitro evaluation of ultrasound effectiveness in controlling doxorubicin release from albumin-conjugated liposomes | |
AlSawaftah et al. | Effect of high-frequency ultrasound on targeted liposomes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220606 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221121 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230221 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230405 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230615 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230704 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230710 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7318876 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |